Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

348.43 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
News headline image
Institutional Titans Bet Big on Amgen as Dividend Yield Hits 2.9% Benchmark
In a decisive show of confidence for the biotechnology sector, institutional heavyweights have significantly ramped up their positions in Amgen (NASDAQ: AMGN) throughout the first quarter of 2026.... 
Via MarketMinute
Topics ETFs Earnings
News headline image
FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market
In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of... 
Via MarketMinute
News headline image
Anthropic Is Worth $380 Billion: This Little-Known ETF Could Let You Own a Piece Before It IPOs ↗
Anthropic recently closed a $30 billion Series G funding round valuing the company at $380 billion. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown
The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report ↗
Amgen Inc. (NASDAQ: AMGN) and GSK plc (NYSE: GSK) are reportedly set to announce their partnership with TrumpRx.gov. This collaboration is set to offer substantial discounts on prescription drugs. 
Via Benzinga
News headline image
1 ETF That Could Turn $100 Per Month Into $67,380 ↗
How does solid growth -- plus a 3.3% dividend yield sound? 
Via The Motley Fool
Topics ETFs Economy World Trade
News headline image
2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that mos... 
Via StockStory
Topics Energy
News headline image
Rapid Micro (RPID) Earnings Call Transcript ↗
Rapid Micro (RPID) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Q4 Earnings Highs And Lows: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Amgen (NASDAQ:AMGN) and its p... 
Via StockStory
Topics Artificial Intelligence
News headline image
Better Weight Loss Stock: Novo Nordisk Vs. Amgen ↗
They may appeal to different kinds of investors. 
Via The Motley Fool
News headline image
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗
The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
2 Profitable Stocks with Solid Fundamentals and 1 Facing Headwinds
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
A Couple's Financial Manifesto, Revisited ↗
There's nothing more romantic than talking about money with your partner. Right? 
Via The Motley Fool
Topics Stocks
News headline image
The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026
As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial
The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a... 
Via MarketMinute
News headline image
Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head
Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing... 
Via MarketMinute
News headline image
Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial
COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated... 
Via MarketMinute
Topics Earnings
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
News headline image
1 Momentum Stock to Research Further and 2 We Avoid
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant... 
Via StockStory
News headline image
The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth
In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion... 
Via MarketMinute
Topics Earnings Economy
News headline image
Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation
As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive,... 
Via MarketMinute
Topics Artificial Intelligence ETFs Government
News headline image
1 Large-Cap Stock Worth Your Attention and 2 We Avoid
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for... 
Via StockStory
News headline image
The 5 Most Interesting Analyst Questions From Amgen’s Q4 Earnings Call
Amgen’s fourth-quarter results reflected broad-based sales growth across its diverse portfolio, with management crediting strong volume gains in key products such as Repatha, Evenity, and Tezspire. CEO... 
Via StockStory
Topics Earnings
News headline image
The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts
In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a... 
Via MarketMinute
Topics Earnings Economy
News headline image
Trump Administration To Launch TrumpRx Platform For Discounted Drugs Later On Thursday: Reports ↗
The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes... 
Via Stocktwits
Topics Economy Government World Trade
News headline image
Healthcare Titans Propel Dow to Record Highs as GLP-1 Sales Spark Major Market Rotation
As the first week of February 2026 unfolds, a dramatic shift in investor sentiment has split the U.S. stock market. While technology and artificial intelligence stocks have faced a sharp pullback, the... 
Via MarketMinute
Topics Artificial Intelligence Earnings Intellectual Property
News headline image
These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys? ↗
Wegovy might be getting more competition soon. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The $1 Trillion Apothecary: A Deep-Dive Research Report on Eli Lilly (LLY)
As of February 5, 2026, Eli Lilly and Company (NYSE: LLY) stands as a paradigm-shifting titan in the global healthcare landscape. Having recently crossed the historic $1 trillion market capitalization... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Why Is Amgen Stock Falling Premarket? ↗
Wall Street’s updated price targets on Amgen imply a wide range from about 16% downside to a 15% upside from the stock’s last close. 
Via Stocktwits
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.